| Literature DB >> 35977169 |
Francis C Motta1, Kevin A McGoff2, Anastasia Deckard3, Cameron R Wolfe4, Mattia Bonsignori5,6, M Anthony Moody7, Kyle Cavanaugh8, Thomas N Denny6, John Harer9, Steven B Haase10.
Abstract
Importance: The importance of surveillance testing and quarantine on university campuses to limit SARS-CoV-2 transmission needs to be reevaluated in the context of a complex and rapidly changing environment that includes vaccines, variants, and waning immunity. Also, recent US Centers for Disease Control and Prevention guidelines suggest that vaccinated students do not need to participate in surveillance testing. Objective: To evaluate the use of surveillance testing and quarantine in a fully vaccinated student population for whom vaccine effectiveness may be affected by the type of vaccination, presence of variants, and loss of vaccine-induced or natural immunity over time. Design Setting and Participants: In this simulation study, an agent-based Susceptible, Exposed, Infected, Recovered model was developed with some parameters estimated using data from the 2020 to 2021 academic year at Duke University (Durham, North Carolina) that described a simulated population of 5000 undergraduate students residing on campus in residential dormitories. This study assumed that 100% of residential undergraduates are vaccinated. Under varying levels of vaccine effectiveness (90%, 75%, and 50%), the reductions in the numbers of positive cases under various mitigation strategies that involved surveillance testing and quarantine were estimated. Main Outcomes and Measures: The percentage of students infected with SARS-CoV-2 each day for the course of the semester (100 days) and the total number of isolated or quarantined students were estimated.Entities:
Mesh:
Year: 2021 PMID: 35977169 PMCID: PMC8727034 DOI: 10.1001/jamahealthforum.2021.3035
Source DB: PubMed Journal: JAMA Health Forum ISSN: 2689-0186
Figure 1. Estimated Daily Infection Prevalence With and Without Surveillance Testing
Figure 2. Estimated Daily Infection Prevalence in Quarantining vs Testing Contacts
Estimated Cumulative Infection Prevalence Across Conditions and Mitigations
| Population parameters | Mitigation strategies, % (IQR) | |||||
|---|---|---|---|---|---|---|
| Vaccine effectiveness | Interaction multiplier | Outside community prevalence, % | None | Surveillance only | Surveillance and quarantining contacts | Surveillance and testing contacts |
| 90% | 1 | 0.1 | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) |
| 1.0 | 0.4 (0.1) | 0.4 (0.1) | 0.5 (0.1) | 0.4 (0.1) | ||
| 10 | 0.1 | 0.6 (0.2) | 0.5 (0.2) | 0.5 (0.1) | 0.5 (0.2) | |
| 1.0 | 3.6 (0.5) | 2.9 (0.3) | 2.9 (0.3) | 2.9 (0.3) | ||
| 20 | 0.1 | 1.6 (0.5) | 0.9 (0.2) | 0.9 (0.2) | 0.8 (0.2) | |
| 1.0 | 11.2 (1.3) | 6.4 (0.6) | 6.1 (0.6) | 6.2 (0.5) | ||
| 75% | 1 | 0.1 | 0.3 (0.1) | 0.3 (0.1) | 0.3 (0.1) | 0.3 (0.1) |
| 1.0 | 0.8 (0.2) | 0.8 (0.2) | 0.8 (0.2) | 0.8 (0.2) | ||
| 10 | 0.1 | 2.8 (1.1) | 1.2 (0.3) | 1.1 (0.3) | 1.1 (0.2) | |
| 1.0 | 18.5 (2.0) | 8.6 (0.6) | 8.1 (0.7) | 8.0 (0.7) | ||
| 20 | 0.1 | 55.8 (6.1) | 3.6 (1.0) | 3.0 (0.8) | 2.7 (0.6) | |
| 1.0 | 74.9 (1.4) | 24.5 (1.8) | 21.1 (1.5) | 20.1 (1.3) | ||
| 50% | 1 | 0.1 | 0.4 (0.1) | 0.4 (0.1) | 0.3 (0.1) | 0.3 (0.1) |
| 1.0 | 1.6 (0.2) | 1.5 (0.2) | 1.5 (0.2) | 1.5 (0.3) | ||
| 10 | 0.1 | 55.8 (6.0) | 3.6 (1.0) | 3.0 (0.8) | 2.7 (0.6) | |
| 1.0 | 75.0 (1.4) | 24.5 (1.6) | 21.2 (1.5) | 20.2 (1.1) | ||
| 20 | 0.1 | 96.6 (0.4) | 44.8 (7.3) | 26.5 (5.7) | 20.1 (5.1) | |
| 1.0 | 97.4 (0.3) | 74.3 (2.0) | 61.7 (2.2) | 57.6 (2.1) | ||
The medians (IQRs) of the fraction of cumulative infections in a modeled population of 5000 individuals over 100 simulations of each choice of population parameters and mitigation strategy. For mitigation strategies involving contact tracing, the contact tracing efficacy was fixed at 15%. Simulations were initialized with 0.1% (5) expected initial exposures and 0.1% (5) expected initial infections.
Estimated Maximum Fraction of Isolated and Quarantined Individuals
| Population parameters | Mitigation strategies % (IQR) | ||||
|---|---|---|---|---|---|
| Vaccine effectiveness | Interaction multiplier | Outside community prevalence, % | Surveillance only | Surveillance and quarantining contacts | Surveillance and testing contacts |
| 90% | 1 | 0.1 | 0.1 (0.1) | 0.4 (0.2) | 0.1 (0.1) |
| 1.0 | 0.1 (0.1) | 0.5 (0.2) | 0.1 (0.1) | ||
| 10 | 0.1 | 0.2 (0.1) | 0.5 (0.2) | 0.2 (0.1) | |
| 1.0 | 0.4 (0.1) | 1.3 (0.2) | 0.5 (0.1) | ||
| 20 | 0.1 | 0.2 (0.1) | 0.6 (0.2) | 0.2 (0.1) | |
| 1.0 | 0.9 (0.1) | 2.5 (0.4) | 0.9 (0.1) | ||
| 75% | 1 | 0.1 | 0.1 (0.1) | 0.4 (0.2) | 0.1 (0.1) |
| 1.0 | 0.2 (0.1) | 0.5 (0.2) | 0.2 (0.1) | ||
| 10 | 0.1 | 0.2 (0.1) | 0.7 (0.3) | 0.2 (0.1) | |
| 1.0 | 1.1 (0.2) | 3.3 (0.6) | 1.1 (0.2) | ||
| 20 | 0.1 | 0.6 (0.2) | 1.5 (0.5) | 0.5 (0.1) | |
| 1.0 | 3.2 (0.4) | 7.7 (0.9) | 2.7 (0.3) | ||
| 50% | 1 | 0.1 | 0.2 (0.1) | 0.4 (0.2) | 0.1 (0.1) |
| 1.0 | 0.3 (0.1) | 0.8 (0.2) | 0.3 (0.0) | ||
| 10 | 0.1 | 0.6 (0.2) | 1.5 (0.5) | 0.5 (0.1) | |
| 1.0 | 3.2 (0.4) | 7.8 (1.0) | 2.7 (0.3) | ||
| 20 | 0.1 | 7.8 (1.4) | 12.0 (3.2) | 3.3 (0.8) | |
| 1.0 | 14.7 (1.2) | 28.2 (2.8) | .3 (1.0) | ||
The medians (IQRs) of the daily maximum fraction of agents in isolation or quarantine in a modeled population of 5000 individuals for 100 simulations of each choice of population parameters and mitigation strategies. For mitigation strategies involving contact tracing, the contact tracing efficacy was fixed at 15%. Simulations were initialized with 0.1% (5) expected initial exposures and 0.1% (5) expected initial infections.